Inhibition of Orthotopic Genital Cancer Induced by Subcutaneous Administration of Human Papillomavirus Peptide Vaccine with CpG Oligodeoxynucleotides as an Adjuvant in Mice

References

• Bray F , Ferlay J , Soerjomataram I , Siegel RL , Torre LA , Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin . 2018;68(6):394–424.30207593
   PubMed Web of Science ®Google Scholar
• Crosbie EJ , Einstein MH , Franceschi S , Kitchener HC . Human papillomavirus and cervical cancer. Lancet . 2013;382(9895):889–899.23618600
   PubMed Web of Science ®Google Scholar
• Castellsague X . Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol . 2008;110(3 Suppl 2):S4–7.18760711
   PubMed Web of Science ®Google Scholar
• Villa LL . HPV prophylactic vaccination: the first years and what to expect from now. Cancer Lett . 2011;305(2):106–112.21190794
   PubMed Web of Science ®Google Scholar
• Yang A , Farmer E , Wu TC , Hung CF . Perspectives for therapeutic HPV vaccine development. J Biomed Sci . 2016;23(1):75.27809842
   PubMed Web of Science ®Google Scholar
• Mohebbi A , Ebrahimzadeh MS , Baghban Rahimi S , et al. Non-replicating Newcastle Disease Virus as an adjuvant for DNA vaccine enhances antitumor efficacy through the induction of TRAIL and granzyme B expression. Virus Res . 2019;261:72–80.30599161
   PubMed Web of Science ®Google Scholar
• van Poelgeest MI , Welters MJ , van Esch EM , et al. HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a Phase II trial. J Transl Med . 2013;11:88.23557172
   PubMed Web of Science ®Google Scholar
• Piersma SJ . Immunosuppressive tumor microenvironment in cervical cancer patients. Cancer Microenviron . 2011;4(3):361–375.21626415
   PubMedGoogle Scholar
• Mestecky J , Moldoveanu Z , Russell MW . Immunologic uniqueness of the genital tract: challenge for vaccine development. Am J Reprod Immunol . 2005;53(5):208–214.15833098
   PubMed Web of Science ®Google Scholar
• Yang Y , Che Y , Zhao Y , Wang X . Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo. Int Immunopharmacol . 2019;69:279–288.30743204
   PubMed Web of Science ®Google Scholar
• Che Y , Yang Y , Suo J , An Y , Wang X . Induction of systemic immune responses and reversion of immunosuppression in the tumor microenvironment by a therapeutic vaccine for cervical cancer. Cancer Immunol Immunother . 2020.
   Web of Science ®Google Scholar
• Burke JD , Young HA . IFN-gamma: a cytokine at the right time, is in the right place. Semin Immunol . 2019;43:101280.31221552
   PubMed Web of Science ®Google Scholar
• Ho IC , Miaw SC . Regulation of IL-4 expression in immunity and diseases. Adv Exp Med Biol . 2016;941:31–77.27734408
   PubMed Web of Science ®Google Scholar
• Melincovici CS , Bosca AB , Susman S , et al. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Rom J Morphol Embryol . 2018;59(2):455–467.30173249
   PubMed Web of Science ®Google Scholar
• Nagarsheth N , Wicha MS , Zou W . Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol . 2017;17(9):559–572.28555670
   PubMed Web of Science ®Google Scholar
• Azevedo Martins JM , Rabelo-Santos SH , do Amaral Westin MC , Zeferino LC . Tumoral and stromal expression of MMP-2, MMP-9, MMP-14, TIMP-1, TIMP-2, and VEGF-A in cervical cancer patient survival: a competing risk analysis. BMC Cancer . 2020;20(1):660.32669083
   PubMed Web of Science ®Google Scholar
• Ohlund D , Elyada E , Tuveson D . Fibroblast heterogeneity in the cancer wound. J Exp Med . 2014;211(8):1503–1523.25071162
   PubMed Web of Science ®Google Scholar
• Avall-Lundqvist EH , Silfversward C , Aspenblad U , Nilsson BR , Auer GU . The impact of tumour angiogenesis, p53 overexpression and proliferative activity (MIB-1) on survival in squamous cervical carcinoma. Eur J Cancer . 1997;33(11):1799–1804.9470836
   PubMed Web of Science ®Google Scholar
• Huang LW , Chou YY , Chao SL , Chen TJ , Lee TT . p53 and p21 expression in precancerous lesions and carcinomas of the uterine cervix: overexpression of p53 predicts poor disease outcome. Gynecol Oncol . 2001;83(2):348–354.11606096
   PubMed Web of Science ®Google Scholar
• Davidson B , Goldberg I , Kopolovic J , et al. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma--a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol . 1999;73(3):372–382.10366463
   PubMed Web of Science ®Google Scholar
• Li LT , Jiang G , Chen Q , Zheng JN . Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep . 2015;11(3):1566–1572.25384676
   PubMed Web of Science ®Google Scholar
• Chen B , Hou ZH , Dong Z , Li CD . Crocetin downregulates the proinflammatory cytokines in methylcholanthrene-induced rodent tumor model and inhibits COX-2 expression in cervical cancer cells. Biomed Res Int . 2015;2015:829513.25874230
   PubMed Web of Science ®Google Scholar
• Hiroshima Y , Zhang Y , Zhang N , et al. Establishment of a patient-derived orthotopic Xenograft (PDOX) model of HER-2-positive cervical cancer expressing the clinical metastatic pattern. PLoS One . 2015;10(2):e0117417.25689852
   PubMed Web of Science ®Google Scholar
• Zong S , Wang X , Yang Y , et al. The use of cisplatin-loaded mucoadhesive nanofibers for local chemotherapy of cervical cancers in mice. Eur J Pharm Biopharm . 2015;93:127–135.25843238
   PubMed Web of Science ®Google Scholar
• Yang M , Yu T , Wang YY , et al. Vaginal delivery of paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth. Adv Healthc Mater . 2014;3(7):1044–1052.24339398
   PubMed Web of Science ®Google Scholar
• Nardelli-Haefliger D , Dudda JC , Romero P . Vaccination route matters for mucosal tumors. Sci Transl Med . 2013;5(172):172–174.
   Web of Science ®Google Scholar
• Sierra G , Dorta-Estremera S , Hegde VL , Nookala SMK , Yanamandra AV , Sastry KJ . Intranasal therapeutic peptide vaccine promotes efficient induction and trafficking of Cytotoxic T cell response for the clearance of HPV vaginal tumors. Vaccines (Basel . 2020;8:2.
   Web of Science ®Google Scholar
• Li S , Zhu W , Ye C , et al. Local mucosal immunization of self-assembled nanofibers elicits robust antitumor effects in an orthotopic model of mouse genital tumors. Nanoscale . 2020;12(5):3076–3089.31965136
   PubMed Web of Science ®Google Scholar
• Lee SE , Hong SH , Verma V , et al. Flagellin is a strong vaginal adjuvant of a therapeutic vaccine for genital cancer. Oncoimmunology . 2016;5(2):e1081328.27057462
   PubMed Web of Science ®Google Scholar
• Decrausaz L , Domingos-Pereira S , Duc M , et al. Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors. Int J Cancer . 2011;129(3):762–772.21384340
   PubMed Web of Science ®Google Scholar
• Bos R , Sherman LA . CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res . 2010;70(21):8368–8377.20940398
   PubMed Web of Science ®Google Scholar
• Wong SB , Bos R , Sherman LA . Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol . 2008;180(5):3122–3131.18292535
   PubMed Web of Science ®Google Scholar
• Marzo AL , Kinnear BF , Lake RA , et al. Tumor-specific CD4+ T cells have a major “post-licensing” role in CTL mediated anti-tumor immunity. J Immunol . 2000;165(11):6047–6055.11086036
   PubMed Web of Science ®Google Scholar
• Quezada SA , Simpson TR , Peggs KS , et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med . 2010;207(3):637–650.20156971
   PubMed Web of Science ®Google Scholar
• Matsuzaki J , Tsuji T , Luescher IF , et al. Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses. Sci Rep . 2015;5:14896.26447332
   PubMed Web of Science ®Google Scholar
• Qin Z , Blankenstein T . CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity . 2000;12(6):677–686.10894167
   PubMed Web of Science ®Google Scholar
• Najafi M , Farhood B , Mortezaee K . Contribution of regulatory T cells to cancer: a review. J Cell Physiol . 2019;234(6):7983–7993.30317612
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI , Nagaraj S . Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol . 2009;9(3):162–174.19197294
   PubMed Web of Science ®Google Scholar
• Manrique SZ , Correa MA , Hoelzinger DB , et al. Foxp3-positive macrophages display immunosuppressive properties and promote tumor growth. J Exp Med . 2011;208(7):1485–1499.21670203
   PubMed Web of Science ®Google Scholar
• Qian BZ , Li J , Zhang H , et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature . 2011;475(7355):222–225.21654748
   PubMed Web of Science ®Google Scholar
• Kitamura T , Qian BZ , Soong D , et al. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J Exp Med . 2015;212(7):1043–1059.26056232
   PubMed Web of Science ®Google Scholar
• Kumar V , Patel S , Tcyganov E , Gabrilovich DI . The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol . 2016;37(3):208–220.26858199
   PubMed Web of Science ®Google Scholar
• Shi H , Zhang J , Han X , et al. Recruited monocytic myeloid-derived suppressor cells promote the arrest of tumor cells in the premetastatic niche through an IL-1beta-mediated increase in E-selectin expression. Int J Cancer . 2017;140(6):1370–1383.27885671
   PubMed Web of Science ®Google Scholar
• Xu Y , Dong X , Qi P , et al. Sox2 communicates with tregs through CCL1 to promote the stemness property of breast cancer cells. Stem Cells . 2017;35(12):2351–2365.29044882
   PubMed Web of Science ®Google Scholar
• Chauhan SK , Saban DR , Dohlman TH , Dana RCCL . 21 conditioned regulatory T cells induce allotolerance through enhanced homing to lymphoid tissue. J Immunol . 2014;192(2):817–823.24337379
   PubMed Web of Science ®Google Scholar
• Stamenkovic I . Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol . 2000;10(6):415–433.11170864
   PubMed Web of Science ®Google Scholar
• Crawford HC , Matrisian LM . Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis . 1994;14(1–6):234–245.7657516
   PubMedGoogle Scholar
• Arguello-Ramirez J , Perez-Cardenas E , Delgado-Chavez R , Solorza-Luna G , Villa-Trevino S , Arenas-Huertero F . Matrix metalloproteinases-2, −3, and −9 secreted by explants of benign and malignant lesions of the uterine cervix. Int J Gynecol Cancer . 2004;14(2):333–340.15086734
   PubMed Web of Science ®Google Scholar
• Davidson B , Goldberg I , Kopolovic J , et al. Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix-clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol . 1999;72(3):380–386.10053110
   PubMed Web of Science ®Google Scholar